Unisys Corporation enters the post-earnings window having silenced the bears — at least for now.
The company reported Q1 2026 results on May 5, and the headline numbers were better than feared. Adjusted EPS came in at $(0.14), beating the $(0.31) consensus by $0.17. Revenue hit $437.6M, clearing the $415.7M estimate by a meaningful margin. Full-year guidance was affirmed at $1.876B–$1.915B. The stock has responded: it's up 38% in a month and 6.8% this week alone to $2.84, a move that puts a genuine dent in the short thesis.
Short sellers are pulling back, but the position is still substantial. SI as a percentage of free float dropped from a peak near 8.3% in late March to 7.8% now — a six-week decline that tracks the stock's rise. The retreat has been orderly rather than panicked. Weekly short interest fell just 2.1%, and the month-on-month reduction is 4.1%, suggesting covering activity but no signs of a disorderly squeeze. The lending market reflects that calm. Cost to borrow is minimal at 0.50% — barely a rounding error — and availability remains loose enough that new shorts face no structural squeeze pressure. Borrow is far from tight.
Options positioning, however, tells a noticeably more defensive story than the headline price move might imply. The put/call ratio sits at 1.58, close to its 20-day average of 1.61 and well above the mid-March regime of roughly 1.05 that prevailed for much of April's first half. The shift happened abruptly around April 18-20, when the PCR jumped from ~1.04 to over 2.5 in three sessions, and it has since eased modestly but not fully unwound. The 52-week PCR low of 0.36 remains a distant memory. Options traders remain more hedged than usual for this name, even after the earnings beat.
The Street's stance on UIS is broadly constructive but dated. The most recent analyst action in the data comes from Needham in late February, where analyst Mayank Tandon reiterated a Buy with a $4.00 target — roughly 41% above current levels of $2.84. William Blair initiated at Outperform in December, and Jefferies set a Hold at $4.00 in September. The consensus analyst return potential is a substantial 71.6%, which reflects both genuine optimism and the fact that most targets were set before the stock's decline to the low $2s. With the stock now trading at $2.84 after a 38% rally, some of those targets from the $4–$6 range may simply not have been updated recently enough to be actionable. The EV/EBITDA multiple has edged up to 1.9x — still extremely compressed — while the P/E ratio of 3.7x has expanded about 0.9 points over the past month as the price has recovered. RSI14 at 72.8 signals the stock is technically overbought after its run, a level that often precedes consolidation.
The institutional picture is worth noting. Vanguard holds 9.8% of shares. D.E. Shaw added 406,000 shares to reach 4.8%, and Millennium Management added 878,000 shares to reach 3.6% — both positions built as of December 31. Saba Capital added 616,000 shares to 2.1%. The cluster of smart-money accumulation in Q4 2025 aligns with the mid-$2s base from which the stock has now begun to lift. On the insider side, a broad group of officers — including CFO Michael Thomson and COO Chris Arrasmith — sold small token amounts at $2.43 on February 26-27. The values involved were de minimis in dollar terms, strongly suggesting these were tax-withholding disposals tied to vesting events, not conviction selling. The 90-day net insider position is actually modestly positive at ~215,000 shares.
The bear case rests on the structural pressures that persist beneath the earnings-beat surface: non-GAAP operating margins guided for decline in FY25, net leverage of 3.5x against a peer median of 0.8x, and a revenue growth range spanning -1% to +1% in constant currency. The bull case points to the 15% year-on-year jump in Total Contract Value on new business in the second half of 2025, along with stabilising revenues in the Enterprise Computing Solutions segment. The next scheduled event is a Q1 earnings call on June 2 — what to watch there is whether the revenue beats translate into any upward revision to the full-year guidance bands, and whether management addresses the leverage trajectory directly.
See the live data behind this article on ORTEX.
Open UIS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
